Reports Summarize Head and Neck Cancer Study Results from Ningbo University (Identification and validation of a novel signature based on T cell marker genes to predict prognosis, immunotherapy response and chemotherapy sensitivity in head and...).

A recent study conducted by researchers at Ningbo University in China aimed to develop a reliable signature using T cell marker genes (TMGs) to predict the prognosis and therapy responsiveness of head and neck squamous cell carcinoma (HNSCC) patients. The study found that patients with high-risk scores based on the TMG signature had unfavorable progression-free survival, disease-specific survival, and overall survival. On the other hand, low-risk patients had a higher percentage of infiltrating immune cells and a higher incidence rate of immune-related events, suggesting favorable responsiveness to immunotherapy. Additionally, high-risk patients showed a greater degree of sensitivity to chemotherapy agents. The TMG signature identified in this study can serve as a prognostic marker and guide individualized immunotherapy and chemotherapy selection for HNSCC patients. [Extracted from the article]

Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)